vs
Side-by-side financial comparison of Arcutis Biotherapeutics, Inc. (ARQT) and CENTERSPACE (CSR). Click either name above to swap in a different company.
Arcutis Biotherapeutics, Inc. is the larger business by last-quarter revenue ($129.5M vs $65.1M, roughly 2.0× CENTERSPACE). Arcutis Biotherapeutics, Inc. runs the higher net margin — 13.4% vs -23.0%, a 36.4% gap on every dollar of revenue. On growth, Arcutis Biotherapeutics, Inc. posted the faster year-over-year revenue change (81.5% vs -3.0%). Over the past eight quarters, Arcutis Biotherapeutics, Inc.'s revenue compounded faster (70.1% CAGR vs 0.0%).
Arcutis Biotherapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing and commercializing innovative prescription therapies for immune-mediated dermatological diseases. Its core product portfolio targets conditions including psoriasis, atopic dermatitis, and alopecia areata, primarily serving patients and healthcare providers across the United States, addressing unmet needs in the dermatology care segment.
Centerspace is a real estate investment company specializing in the ownership, operation, and development of high-quality multifamily residential properties. Its core operating markets cover the U.S. Midwest and Mountain West regions, serving diverse renter segments with both affordable and premium housing options, while focusing on tenant experience and long-term asset value growth.
ARQT vs CSR — Head-to-Head
Income Statement — Q2 FY2026 vs Q1 FY2026
| Metric | | |
|---|---|---|
| Revenue | $129.5M | $65.1M |
| Net Profit | $17.4M | $-15.0M |
| Gross Margin | 91.0% | — |
| Operating Margin | 14.2% | — |
| Net Margin | 13.4% | -23.0% |
| Revenue YoY | 81.5% | -3.0% |
| Net Profit YoY | — | -258.1% |
| EPS (diluted) | $0.13 | $-0.49 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q2 26 | $129.5M | — | ||
| Q1 26 | $105.4M | $65.1M | ||
| Q4 25 | $129.5M | $66.6M | ||
| Q3 25 | $99.2M | $71.4M | ||
| Q2 25 | $81.5M | $68.5M | ||
| Q1 25 | $65.8M | $67.1M | ||
| Q4 24 | $71.4M | $66.4M | ||
| Q3 24 | $44.8M | $65.0M |
| Q2 26 | $17.4M | — | ||
| Q1 26 | $-11.3M | $-15.0M | ||
| Q4 25 | $17.4M | $-18.4M | ||
| Q3 25 | $7.4M | $53.8M | ||
| Q2 25 | $-15.9M | $-14.5M | ||
| Q1 25 | $-25.1M | $-3.7M | ||
| Q4 24 | $-10.8M | $-5.1M | ||
| Q3 24 | $-41.5M | $-1.0M |
| Q2 26 | 91.0% | — | ||
| Q1 26 | 90.7% | — | ||
| Q4 25 | 91.0% | 96.5% | ||
| Q3 25 | 91.2% | 96.5% | ||
| Q2 25 | 90.8% | 96.5% | ||
| Q1 25 | 86.6% | 96.4% | ||
| Q4 24 | 90.3% | 96.5% | ||
| Q3 24 | 87.7% | 96.6% |
| Q2 26 | 14.2% | — | ||
| Q1 26 | -8.6% | — | ||
| Q4 25 | 14.2% | -15.9% | ||
| Q3 25 | 8.6% | — | ||
| Q2 25 | -17.9% | -9.9% | ||
| Q1 25 | -37.3% | 7.1% | ||
| Q4 24 | -10.7% | 4.3% | ||
| Q3 24 | -87.3% | 9.8% |
| Q2 26 | 13.4% | — | ||
| Q1 26 | -10.7% | -23.0% | ||
| Q4 25 | 13.4% | -27.7% | ||
| Q3 25 | 7.5% | 75.3% | ||
| Q2 25 | -19.5% | -21.2% | ||
| Q1 25 | -38.1% | -5.6% | ||
| Q4 24 | -15.1% | -7.6% | ||
| Q3 24 | -92.8% | -1.6% |
| Q2 26 | $0.13 | — | ||
| Q1 26 | $-0.09 | $-0.49 | ||
| Q4 25 | $0.14 | $-1.08 | ||
| Q3 25 | $0.06 | $3.19 | ||
| Q2 25 | $-0.13 | $-0.87 | ||
| Q1 25 | $-0.20 | $-0.22 | ||
| Q4 24 | $-0.09 | $-0.31 | ||
| Q3 24 | $-0.33 | $-0.40 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $42.9M | $7.6M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $189.5M | $695.0M |
| Total Assets | $433.0M | $1.9B |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q2 26 | $42.9M | — | ||
| Q1 26 | $34.8M | $7.6M | ||
| Q4 25 | $42.9M | $12.8M | ||
| Q3 25 | $47.1M | $12.9M | ||
| Q2 25 | $72.7M | $12.4M | ||
| Q1 25 | $53.1M | $11.9M | ||
| Q4 24 | $71.3M | $12.0M | ||
| Q3 24 | $134.9M | $14.5M |
| Q2 26 | — | — | ||
| Q1 26 | — | — | ||
| Q4 25 | $109.0M | $1.0B | ||
| Q3 25 | $108.5M | $1.1B | ||
| Q2 25 | $108.0M | $1.1B | ||
| Q1 25 | $107.6M | $955.5M | ||
| Q4 24 | $107.2M | $955.4M | ||
| Q3 24 | $204.6M | $921.3M |
| Q2 26 | $189.5M | — | ||
| Q1 26 | $189.6M | $695.0M | ||
| Q4 25 | $189.5M | $719.2M | ||
| Q3 25 | $158.1M | $748.6M | ||
| Q2 25 | $139.0M | $710.1M | ||
| Q1 25 | $142.7M | $636.8M | ||
| Q4 24 | $157.5M | $752.0M | ||
| Q3 24 | $156.6M | $672.5M |
| Q2 26 | $433.0M | — | ||
| Q1 26 | $460.0M | $1.9B | ||
| Q4 25 | $433.0M | $1.9B | ||
| Q3 25 | $371.0M | $2.1B | ||
| Q2 25 | $352.4M | $2.0B | ||
| Q1 25 | $344.1M | $1.9B | ||
| Q4 24 | $348.9M | $1.9B | ||
| Q3 24 | $437.4M | $1.9B |
| Q2 26 | — | — | ||
| Q1 26 | — | — | ||
| Q4 25 | 0.58× | 1.42× | ||
| Q3 25 | 0.69× | 1.53× | ||
| Q2 25 | 0.78× | 1.57× | ||
| Q1 25 | 0.75× | 1.50× | ||
| Q4 24 | 0.68× | 1.27× | ||
| Q3 24 | 1.31× | 1.37× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
